Award type :
Product Development Award
Product Development Award
Product type :
Vaccines
Vaccines
Award year :
2020
2020
Project start date :
2020 / 08 / 14
2020 / 08 / 14
Project end date :
2021 / 09 / 30
2021 / 09 / 30
Project duration (months) :
13
13
Development stage :
Preclinical
Preclinical
Target disease :
Influenza, Respiratory
Influenza, Respiratory
Region served :
World
World
Recipient organization / Country of funding recipient organization :
Genexine / Republic of Korea
Genexine / Republic of Korea
Collaborator(s) / Country :
-
-
Funding amount(KRW) :
500,000,000
500,000,000
This project by Genexine is a safety study of engineered long-acting IL-7 that enhances the T-cell immune response and provides protection in an influenza lethality model. This vaccine reflects a pathogen agnostic approach and can be used in future outbreaks of viral respiratory infections.